Dr. Daniel Engelman, MD
Claim this profileBaystate Health
Studies Coronary Artery Disease
Studies Heart Disease
3 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Daniel Engelman, MD is currently running
Single vs Multiple Arterial Grafts
for Heart Disease
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups.
Recruiting1 award N/A4 criteria
Anticoagulation + Antiplatelet Therapy
for Post-Operative Atrial Fibrillation
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
Recruiting2 awards Phase 32 criteria
More about Daniel Engelman, MD
Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Daniel Engelman, MD has experience with
- Antiplatelet-only Strategy
- Oral Anticoagulant
- Multiple Arterial Grafting
- Single Arterial Graft
- Multiple Arterial Grafting
- Single Arterial Graft
Breakdown of trials Daniel Engelman, MD has run
Coronary Artery Disease
Heart Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Engelman, MD specialize in?
Daniel Engelman, MD focuses on Coronary Artery Disease and Heart Disease. In particular, much of their work with Coronary Artery Disease has involved treating patients, or patients who are undergoing treatment.
Is Daniel Engelman, MD currently recruiting for clinical trials?
Yes, Daniel Engelman, MD is currently recruiting for 2 clinical trials in Springfield Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Daniel Engelman, MD has studied deeply?
Yes, Daniel Engelman, MD has studied treatments such as Antiplatelet-only strategy, Oral Anticoagulant, Multiple Arterial Grafting.
What is the best way to schedule an appointment with Daniel Engelman, MD?
Apply for one of the trials that Daniel Engelman, MD is conducting.
What is the office address of Daniel Engelman, MD?
The office of Daniel Engelman, MD is located at: Baystate Health, Springfield, Massachusetts 01199 United States. This is the address for their practice at the Baystate Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.